| Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers HX Wu, ZX Wang, Q Zhao, DL Chen, MM He, LP Yang, YN Wang, Y Jin, ... Annals of translational medicine 7 (22), 2019 | 105 | 2019 |
| Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer G Chen, J Peng, Q Xiao, HX Wu, X Wu, F Wang, L Li, P Ding, Q Zhao, Y Li, ... Journal of hematology & oncology 14, 1-11, 2021 | 102 | 2021 |
| Advancing to the era of cancer immunotherapy Y Wang, M Wang, HX Wu, RH Xu Cancer Communications 41 (9), 803-829, 2021 | 97 | 2021 |
| ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells J Cai, J Wang, Y Huang, H Wu, T Xia, J Xiao, X Chen, H Li, Y Qiu, Y Wang, ... Cell death & disease 7 (11), e2459-e2459, 2016 | 97 | 2016 |
| Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response Z Zhang, ZX Wang, YX Chen, HX Wu, L Yin, Q Zhao, HY Luo, ZL Zeng, ... Genome Medicine 14 (1), 45, 2022 | 86 | 2022 |
| Nestin regulates cellular redox homeostasis in lung cancer through the Keap1–Nrf2 feedback loop J Wang, Q Lu, J Cai, Y Wang, X Lai, Y Qiu, Y Huang, Q Ke, Y Zhang, ... Nature Communications 10 (1), 5043, 2019 | 84 | 2019 |
| Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers HX Wu, YX Chen, ZX Wang, Q Zhao, MM He, YN Wang, F Wang, RH Xu Journal for immunotherapy of cancer 7, 1-13, 2019 | 72 | 2019 |
| Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’to ‘accuracy’ HX Wu, ZX Wang, Q Zhao, F Wang, RH Xu Journal for immunotherapy of cancer 7, 1-7, 2019 | 42 | 2019 |
| CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells J Wang, B Zhang, H Wu, J Cai, X Sui, Y Wang, H Li, Y Qiu, T Wang, ... Oncogene 36 (10), 1351-1363, 2017 | 41 | 2017 |
| A nestin–cyclin-dependent kinase 5–dynamin-related protein 1 axis regulates neural stem/progenitor cell stemness via a metabolic shift J Wang, Y Huang, J Cai, Q Ke, J Xiao, W Huang, H Li, Y Qiu, Y Wang, ... Stem Cells 36 (4), 589-601, 2018 | 30 | 2018 |
| Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1–expressing esophageal squamous cell carcinoma: a post hoc … HX Wu, YQ Pan, Y He, ZX Wang, WL Guan, YX Chen, YC Yao, NY Shao, ... Journal of Clinical Oncology 41 (9), 1735, 2023 | 29 | 2023 |
| p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer X Sui, J Cai, H Li, C He, C Zhou, Y Dong, L Chen, B Zhang, Y Wang, ... Cell death & disease 9 (5), 523, 2018 | 29 | 2018 |
| EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers Z Zhang, HX Wu, WH Lin, ZX Wang, LP Yang, ZL Zeng, HY Luo BMC medicine 19, 1-15, 2021 | 28 | 2021 |
| Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment F Wang, YS Huang, HX Wu, ZX Wang, Y Jin, YC Yao, YX Chen, Q Zhao, ... Gut 71 (7), 1340-1349, 2022 | 24 | 2022 |
| Chemotherapy with or without anti-EGFR agents in left-and right-sided metastatic colorectal cancer: an updated meta-analysis ZX Wang, HX Wu, MM He, YN Wang, HY Luo, PR Ding, D Xie, G Chen, ... Journal of the National Comprehensive Cancer Network 17 (7), 805-811, 2019 | 22 | 2019 |
| KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors R Zhang, HX Wu, M Xu, X Xie Biomarker Research 8, 1-5, 2020 | 16 | 2020 |
| Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials ZX Wang, HX Wu, L Xie, WH Lin, F Liang, J Li, ZM Yang, RH Xu Journal for ImmunoTherapy of Cancer 9 (4), 2021 | 14 | 2021 |
| Correlation of milestone restricted mean survival time ratio with overall survival hazard ratio in randomized clinical trials of immune checkpoint inhibitors: a systematic … ZX Wang, HX Wu, L Xie, YN Wang, LP Yang, MM He, HY Luo, PR Ding, ... JAMA Network Open 2 (5), e193433-e193433, 2019 | 13 | 2019 |
| Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced … DY Ruan, YX Chen, XL Wei, YN Wang, ZX Wang, HX Wu, RH Xu, ... Gastroenterology report 9 (6), 560-570, 2021 | 12 | 2021 |
| A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients LP Yang, ZX Wang, MM He, HX Wu, SQ Yuan, W Wang, Y Jin, C Ren, ... Cancer Management and Research, 3993-4003, 2019 | 5 | 2019 |
Qi Zhao 赵齐Associate Professor. Sun Yat-sen University Cancer CenterVerified email at sysucc.org.cn
